Wall Street saw a massive recovery on Friday as the Dow Jones Industrial Average soared 1,050 points (2.15%) to reach a record closing high of 49,958.72. This rally successfully erased the losses from the previous day’s tech-driven slump. The S&P 500 and Nasdaq Composite also posted gains of 1.2% and 1.0%, respectively, as investor anxiety regarding AI spending began to stabilize.
Tech Sector: A Tale of Two Sides
The technology landscape saw a sharp divide between hardware providers and service giants:
- Chipmakers Rally: Semiconductor stocks bounced back strongly. Nvidia rose 5%, while AMD and Micron saw significant jumps. Investors shifted their focus toward the massive $630 billion in capital expenditure planned by Big Tech for 2026, viewing it as a guaranteed demand for AI hardware.
- Amazon’s Deep Dive: In contrast, Amazon shares tumbled 9%. The market reacted negatively to the company’s plan to spend $200 billion on AI infrastructure in 2026—a figure far higher than anticipated. Concerns over immediate profitability and a lower-than-expected operating income guidance led several brokerages to slash their price targets.
Sector Rotation: Financials and Industrials Lead
The Dow’s record-breaking day was fueled by a rotation into cyclical sectors:
- Banking & Industry: JPMorgan Chase and Caterpillar were among the top performers, gaining 3.2% and 3.9% respectively.
- Economic Optimism: This shift suggests that investors are moving capital away from overpriced tech stocks and into companies that benefit more directly from steady economic growth and lending activity.
Mixed Economic Signals
- Consumer Sentiment: The University of Michigan reported a six-month high in consumer confidence (57.3). However, the gains were uneven; the improvement was mostly seen in wealthy households benefiting from the stock market, while average consumers remain worried about high prices and job security.
- Healthcare Struggles: The healthcare sector faced a significant blow. Molina Healthcare (MOH) crashed 28% after issuing a 2026 earnings forecast that was less than half of what analysts expected. The company cited rising medical costs and poor performance in Medicare Advantage as primary headwinds.
